Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications
View Full Paper
Ask AI
Bookmark
Share
Key result
Empagliflozin significantly increased peak oxygen consumption by 23.9% and reduced the VE/VCO2 slope by 15.8% compared to baseline in patients with type 2 diabetes.
Why the study?
Does empagliflozin improve cardiorespiratory fitness in patients with type 2 diabetes?
Population
20 consecutive patients with type 2 diabetes, established or high risk for cardiovascular disease, and eGFR…
Comparison
Empagliflozin 10 mg orally daily for 3 to 6 months vs Usual care
Design
Cohort
Follow-up
3 to 6 months (mean 170.57 days)
Authors
Discussion
Loading...
Member takes
Implication
May support cardiorespiratory fitness gains in type 2 diabetes; leaves open randomized confirmation of clinical outcomes.
Key Points
- To evaluate the effects of the SGLT2 inhibitor empagliflozin on indices of cardiorespiratory fitness in patients with type 2 diabetes.
- Assigned 20 patients with type 2 diabetes to receive either empagliflozin 10 mg daily or usual care.
- Measured cardiorespiratory fitness indices via cardiopulmonary exercise testing on a cycle ergometer at baseline and 3 to 6 months post-treatment.
- Empagliflozin treatment led to an increase in peak oxygen consumption (VO2).
- Empagliflozin significantly improved ventilatory efficiency (reduced VE/VCO2 slope) and enhanced heart rate recovery post-exercise.
Study Design
Type
Cohort (n=20)
Blinding
Open-label
Multicenter
No
Structured PICO
Does empagliflozin improve cardiorespiratory fitness in patients with type 2 diabetes?
P
Population
20 consecutive patients with type 2 diabetes, established or high risk for cardiovascular disease, and eGFR > 30 mL/min/1.73m2. Mean age ~67, predominantly male. Recruited from a community cardiology clinic in Whitby, Ontario.
I
Intervention
Empagliflozin 10 mg orally daily for 3 to 6 months (mean duration 170.57 days)
C
Comparator
Usual care (standard medical therapy excluding empagliflozin for the management of diabetes and cardiovascular risk)
O
Outcome
Peak oxygen consumption (VO2) and the minute ventilation/carbon dioxide production slope (VE/VCO2) measured by cardiopulmonary exercise testing at 3 to 6 months post-interventionsurrogate
Main Result
Absolute Event Rate: 20.5% vs 19.68%
p-value: p=0.01
Empagliflozin significantly improved markers of cardiorespiratory fitness, including peak VO2 and VE/VCO2 slope, in patients with type 2 diabetes, providing potential mechanistic insights into its cardiovascular benefits.
Limitations
- Small sample size
- Not randomized
- Not powered adequately to assess for the primary outcome
- CPET data was collected by a single analyst who was not blinded to the treatment allocation
- Did not collect data assessing symptom and quality of life improvement
- Only 3/20 patients had evidence of systolic dysfunction, limiting extrapolation to the broader heart failure population
- CPET data collected by a single analyst who was not blinded to treatment allocation
Cite This Study
Kumar et al. (2018) conducted a cohort in Type 2 diabetes and high cardiovascular risk (n=20). Empagliflozin vs. Usual care was evaluated on Peak oxygen consumption (VO2) (p=0.01). Empagliflozin significantly increased peak oxygen consumption by 23.9% and reduced the VE/VCO2 slope by 15.8% compared to baseline in patients with type 2 diabetes.
Topics
View Full Paper
Ask AI
Bookmark
Share